Anti-MAP2 antibody [HM-2] (ab11267)
![Anti-MAP2 antibody [HM-2] (ab11267)](https://www.abcam.com/ps/products/11/ab11267/Images/ab11267-320126-anti-map2-antibody-hm-2-immunofluorescence.jpg "Anti-MAP2 antibody [HM-2] (ab11267)")
Key features and details
- Mouse monoclonal [HM-2] to MAP2
- Suitable for: ICC, WB
- Reacts with: Rat
- Isotype: IgG1
Overview
-
Product name
Anti-MAP2 antibody [HM-2]
See all MAP2 primary antibodies -
Description
Mouse monoclonal [HM-2] to MAP2 -
Host species
Mouse -
Tested Applications & Species
See all applications and species dataApplication Species ICC RatWB Rat
-
Immunogen
Other Immunogen Type corresponding to Rat MAP2. HM-2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from mice immunized with rat brain microtubule associated proteins (MAPs).
-
Positive control
- WB: Rat brain tissue lysate. ICC: B35 cells.
-
General notes
This product was changed from ascites to tissue culture supernatant on 05/06/2019. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
Storage in frost-free freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.40
Preservative: 0.097% Sodium azide
Constituent: 0.0268% PBS -
Concentration information loading... -
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
HM-2 -
Isotype
IgG1 -
Research areas
Images
-
Immunocytochemistry - Anti-MAP2 antibody [HM-2] (ab11267) Bailey, J.A. et al PLoS One. 2011;6(7):e21954. doi: 10.1371/journal.pone.0021954. Epub 2011 Jul 22 Reproduced under the Creative Commons license https://creativecommons.org/publicdomain/zero/1.0/
Rivastigmine preserves neuronal morphology and alters sAPP secretion
At day 12 or day 20, cells were fixed for immunocytochemistry analysis and probed with anti-MAP2 (green) and anti-GFAP (red) antibodies. Neuronal MAP2 immunoreactivity declines to almost undetectable levels between day 12 and day 20 in untreated cells, whereas neuronal morphology is preserved in rivastigmine treated cultures. Glial GFAP was observed to increase in both treated and untreated cells between day 12 and day 20. These results confirm the degeneration of neurons by day 20.
MAP2 is detected using ab11267 in 4% paraformaldehyde-fixed, 0.5% Triton X-100 permeabilized embryonic rat cerebrocortical cells.
(From Figure 2A of Bailey et al)
This image was generated using the ascites version of the product.
-
![Western blot - Anti-MAP2 antibody [HM-2] (ab11267)](https://www.abcam.com/ps/products/11/ab11267/Images/ab11267-320127-267b.jpg)
Western blot - Anti-MAP2 antibody [HM-2] (ab11267)Anti-MAP2 antibody [HM-2] (ab11267) at 1 µg/ml + Rat brain lysate
Predicted band size: 200 kDaThis image was generated using the ascites version of the product.
-
![Immunocytochemistry - Anti-MAP2 antibody [HM-2] (ab11267)](https://www.abcam.com/ps/products/11/ab11267/Images/ab11267-251913-anti-map2-antibody-hm-2-immunofluorescence.jpg)
Immunocytochemistry - Anti-MAP2 antibody [HM-2] (ab11267)Immunocytochemical analysis of B35 (rat neuroblastoma cell line) cells labelling MAP2 with ab11267 at a concentration of 2 μg/mL. The secondary was developed using Goat anti-mouse IgG. Cells were counterstained with DAPI to stain nuclei.
This image was generated using the ascites version of the product.
